pioglitazone + alogliptin + metformin

**pioglitazone + alogliptin + metformin** is a triple oral combination therapy for **type 2 diabetes mellitus**. Each component acts through a complementary mechanism: - **Metformin** is a biguanide that reduces hepatic glucose production and increases peripheral glucose uptake, primarily via activation of AMP-activated protein kinase (AMPK), and may also modestly increase postprandial GLP-1 levels. - **Pioglitazone** is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose, muscle, and hepatic tissues. - **Alogliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases endogenous incretin levels such as GLP-1 and GIP, leading to increased insulin secretion and decreased glucagon release in a glucose-dependent manner. This combination is used to improve glycemic control in patients inadequately controlled on dual therapy or monotherapy, and is supported by phase III clinical trial data showing improved hemoglobin A1c reductions compared to dual therapy. Combination tablets provide a simplified pill burden for patients needing multiple antidiabetic agents[1][2][3][4].

Brand names

Kazano

Other names

alogliptin + Actoplus Metalogliptin and actoplus met